Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | CA12 | O43570 | 1/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.75 |
| ▸ | CA9 | Q16790 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4456317 | 0.98 | BCHE (0.97) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL11476550 | 0.90 | BCHE (1.00) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL13686585 | 0.89 | BCHE (0.79) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL894215 | 0.88 | BCHE (0.85) | BCHEMEN1KMT2A | |
| SCHEMBL7760590 | 0.88 | BCHE (1.00) | BCHEMEN1KMT2A | |
| SCHEMBL11069984 | 0.88 | BCHE (1.00) | BCHEMEN1KMT2A | |
| SCHEMBL13886610 | 0.85 | BCHE (0.74) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL3026043 | 0.85 | BCHE (0.75) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL9154589 | 0.84 | LTA4H (0.79) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL6322772 | 0.84 | BCHE (0.72) | BCHEMEN1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563757-B1 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2016-11-16 | — | — | EP | claimed |
| US-8912360-B2 | Methods for preparing ritodrine hydrochloride | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2014-12-16 | — | — | US | claimed |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2013-05-16 | — | — | US | claimed |
| EP-2563757-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2013-03-06 | — | — | EP | claimed |
| WO-2011134724-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2011-11-03 | — | — | WO | claimed |
| EP-2563757-B1 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2016-11-16 | — | — | EP | disclosed |
| US-8912360-B2 | Methods for preparing ritodrine hydrochloride | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| EP-2563757-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134724-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2011-11-03 | — | — | WO | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7339079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-04 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | TPO, TSHR, THRB | BCHE 332/4885MEN1 179/4885KMT2A 4034/4885 |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | COMT, ADRA2C, ADRA1D | BCHE 68/4885MEN1 2598/4885KMT2A 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.